PROM1 and thyroid gland undifferentiated (anaplastic) carcinoma: A novel CD133 targeting aptamer for treatment of anaplastic thyroid cancer, termed AP-1-M, was selected using cell-SELEX against CD133 expressing Hek293 cells, with counterselection against non-CD133 transfected Hek293 cells 60.